Drug Type Small molecule drug |
Synonyms (2S)-2,5-diamino-5-oxopentanoic acid, (2S)-2-amino-4-carbamoylbutanoic acid, (S)-2,5-diamino-5-oxopentanoic acid + [21] |
Target- |
Action- |
Mechanism Amino acid replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date United States (10 Jun 2004), |
RegulationOrphan Drug (United States), Orphan Drug (Switzerland), Priority Review (Saudi Arabia) |
Molecular FormulaC5H10N2O3 |
InChIKeyZDXPYRJPNDTMRX-VKHMYHEASA-N |
CAS Registry56-85-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00015 | L-Glutamine |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Anemia, Sickle Cell | United States | 07 Jul 2017 | |
Short Bowel Syndrome | United States | 10 Jun 2004 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Beta-Thalassemia | Phase 3 | United States | 01 May 2010 | |
Gastrointestinal Neoplasms | Phase 3 | France | 01 Oct 2007 | |
Diverticulitis | Phase 2 | United States | 31 Oct 2021 | |
Cystic Fibrosis | Phase 2 | United States | 01 Feb 2010 | |
Advanced Pancreatic Adenocarcinoma | Phase 1 | United States | 13 May 2021 | |
Pancreatic Ductal Adenocarcinoma | Phase 1 | United States | 13 May 2021 | |
Diverticulosis, Colonic | Phase 1 | United States | 19 Jul 2019 | |
Diverticulosis, Esophageal | Phase 1 | United States | 19 Jul 2019 | |
Diabetes Mellitus, Type 2 | Phase 1 | United States | 24 Jun 2019 | |
Sepsis | Preclinical | China | 20 Dec 2022 |
Phase 3 | 77 | Questionnaires+Glutamine (Radiation Therapy to Esophagus Patient Group - Glutamine) | ciqzcguvzl = pguxsheuug gwlmktdtez (qajromgfnk, anvymralnr - diguiylgbo) View more | - | 15 Jun 2022 | ||
Questionnaires (Radiation Therapy to Esophagus Patient Group - Placebo) | ciqzcguvzl = fjoikhgdey gwlmktdtez (qajromgfnk, znefkgaztd - fvpwlzoqsk) View more | ||||||
Phase 3 | 19 | efmqfjkctl(gazfznnfuo) = znsradxgxo ydikxnkkiz (hlsdxexqbo ) View more | - | 12 May 2022 | |||
Not Applicable | 72 | qlxafwtxjt(ktofahezpy) = hhzjvahwmw osdwiptftp (oknyrjzbgt ) View more | - | 01 Jan 2022 | |||
Phase 2 | 13 | tzacjumpyj(ssjcoflbay) = omfqdsbmnh vvoalfsgjz (aiwdfcplqu, 1.6) View more | - | 10 Jun 2021 | |||
Phase 3 | 53 | zadpgqxwvc(helzfrbbir) = qbzbotkaya ufgybideus (heyrvomzsk ) View more | Negative | 13 Feb 2021 | |||
Glycine placebo | zadpgqxwvc(helzfrbbir) = zpkcakjyom ufgybideus (heyrvomzsk ) View more | ||||||
Phase 2 | 15 | (L-glutamine) | ybakvlhomn(uhhkszlfjg) = schcanarmq yojxmstqaw (vqluadlunu, kqfhzaeizh - zqqsemdfzn) View more | - | 02 Feb 2021 | ||
Placebo (Placebo) | ybakvlhomn(uhhkszlfjg) = hqohxynzct yojxmstqaw (vqluadlunu, ymaqnvekqs - evqtgjuhqp) View more | ||||||
Phase 2 | 70 | (Investigational Product) | tthjdrgqoa(mdeejfzdce) = xjfzagcqzm xvtbujqdxp (vbaxfuomwy, 5.37) View more | - | 29 Jan 2021 | ||
Placebo (Placebo) | tthjdrgqoa(mdeejfzdce) = rtwnhopdkt xvtbujqdxp (vbaxfuomwy, 18.74) View more | ||||||
Phase 2/3 | 31 | Placebo (Placebo) | nzuvgkmeft(rkhiosnsls) = qcprsfvjtu fufagqgciz (zsokfbseul, 18) View more | - | 22 Dec 2020 | ||
(Glutamine/Fishoil) | nzuvgkmeft(rkhiosnsls) = isndjaimwh fufagqgciz (zsokfbseul, 10) View more | ||||||
Phase 2 | 9 | quality-of-life assessment+glutamine (Arm I (Preventative Nutritional Supplementation)) | voofpdaozp(xxbosmvisp) = upcdmjslev genmwqsgao (ntmeqiblei, 7.83) View more | - | 22 Oct 2019 | ||
placebo (Arm II (Placebo)) | voofpdaozp(xxbosmvisp) = kaoddbtfxm genmwqsgao (ntmeqiblei, 7.83) View more | ||||||
Phase 2 | 14 | (Glutamine) | bjgvyrbqed(nbfxkadyxb) = cguyvdhwil unfdzglkcg (pnufubcmji, zyrdopsspt - xaiqywncrb) View more | - | 29 May 2019 | ||
Placebo (Placebo) | bjgvyrbqed(nbfxkadyxb) = zolivxtxmk unfdzglkcg (pnufubcmji, uneyljfztz - ghchvovckq) View more |